We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    esostrate
Previous Study | Return to List | Next Study

Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy (Esostrate)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02551458
Recruitment Status : Recruiting
First Posted : September 16, 2015
Last Update Posted : September 16, 2015
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon

Brief Summary:

Step 1: Inclusion of eligible patients to carry out a translational search for prognostic and predictive markers of Complete Clinical Response and Pathologic Complete Response (using blood samples and diagnostic biopsies) and to collect data on radiochemotherapy and its toxicity.

The trial will evaluate strategies after neoadjuvant treatment and not RCT protocols. The RCT will thus be chosen by the investigator from published effective schemes in a pre-operative setting or in patients not undergoing surgery.

Evaluation of the response 5 to 6 weeks after the RCT.

Step 2: Randomisation in patients with a complete clinical response:

Arm A: Systematic surgery Arm B: Surveillance and rescue surgery in cases with resectable loco-regional recurrence

Patients not eligible for randomisation will have the possibility to participate in a specific study (information can be obtained from the SAKK group (Switzerland Group Clinical Research on Cancer)).

Condition or disease Intervention/treatment Phase
Epidermoid Carcinoma or Adenocarcinoma of the Thoracic Oesophagus or Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II) Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 Other: Systematic surgery Other: Surveillance and rescue surgery in cases of resectable loco-regional recurrence Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Primary Completion Date : March 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm A: Systematic surgery Other: Systematic surgery
Experimental: Arm B: Surveillance and rescue surgery in cases of resectable Other: Surveillance and rescue surgery in cases of resectable loco-regional recurrence

Primary Outcome Measures :
  1. Proportion of surviving patients [ Time Frame: 1 year after randomisation ]
  2. Disease-free survival [ Time Frame: Up to 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Epidermoid carcinoma (EC) or adenocarcinoma of the thoracic oesophagus or adenocarcinoma of the oesogastric junction (Siewert type I or II) proven histologically
  • Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 after a full investigation
  • Patient considered operable with a curative intent and scheduled to undergo first-line radiochemotherapy in a multidisciplinary meeting
  • Age ≥ 18 years < 75 years
  • Patient with national health insurance cover and who has provided written informed consent for the clinical and biological studies.

Exclusion Criteria:

  • Cancer of the cervical oesophagus (15 to 19 cm from the dental arches)
  • Weight loss > 15% at the recruitment with no improvement after nutritional support
  • Serious comorbidity threatening survival in the short term
  • Contra-indication for radiochemotherapy
  • Other uncured malignant disease in the 5 previous years (except for in situ cervical carcinoma and treated non-melanotic skin cancers)
  • Absence of effective contraception in patients (men or women) able to procreate, pregnant or breast-feeding women
  • Impossibility to follow the trial
  • Legal disqualification (patients in custody or under guardianship)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02551458

Layout table for location contacts
Contact: Laurent BEDENNE 3 80 38 13 14 ext +33 laurent.bedenne@u-bourgogne.fr

Show Show 18 study locations
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier: NCT02551458    
Other Study ID Numbers: Bedenne PHRC N 2013
First Posted: September 16, 2015    Key Record Dates
Last Update Posted: September 16, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell